MedCAC Supports Some PGx Test Regimens, But Calls For Overall Better Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Most studies still are not supplying sufficient data on patient outcomes for genetic and protein-based tests designed to drive medical treatments, the Medicare Evidence Development & Coverage Advisory Committee agreed.
You may also be interested in...
FDA Aims For Flexibility In Upcoming Drug/Companion Diagnostic Guidance
FDA is trying to build flexibility into its drug/diagnostic co-development guidance to address variability in how and when therapeutics and companion diagnostics are developed
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.